No headlines found.
No press releases found.
No news found.
The actively managed Tema Oncology ETF seeks to provide long-term growth by investing in companies operating in the oncology industry. The fund conducts deep and comprehensive research, in an effort to identify those companies that deliver breakthrough solutions at attractive valuations. Example companies include large pharmaceutical firms, diagnostic focused businesses with products used to diagnose cancer (such as liquid biopsies or cancer genomic screening), medical device companies focused on cancer treatment, and healthcare service providers with a specific strategic focus on helping treat and manage cancer.
Tema Oncology ETF trades on the NASDAQ stock market under the symbol CANC.
As of July 29, 2026, CANC stock price declined to $40.75 with 14,308 million shares trading.
CANC has a beta of 0.63, meaning it tends to be less sensitive to market movements. CANC has a correlation of 0.11 to the broad based SPY ETF.
CANC has a market cap of $194.38 million. This is considered a Micro Cap stock.
CANC has outperformed the market in the last year with a price return of +52.1% while the SPY ETF gained +16.6%. CANC has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +9.3% and -0.2%, respectively, while the SPY returned +3.5% and -2.3%, respectively.
CANC support price is $40.49 and resistance is $41.88 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CANC shares will trade within this expected range on the day.
